目的 比较多西他赛联合卡铂方案(TP)与表柔比星联合环磷酰胺序贯多西他赛方案(EC-T)辅助治疗三阴性乳腺癌Ⅲ期的临床疗效和安全性.方法 选取浙江金华广福肿瘤医院2012年5月~2016年10月收治的62例三阴性乳腺癌Ⅲ期患者为研究对象,随机分为对照组和实验组,每组31例.对照组进行表柔比星联合环磷酰胺序贯多西他赛方案治疗,实验组组进行多西他赛联合卡铂方案,比较分析相关临床指标.结果 实验组患者近期缓解率(77.42%)与对照组(74.19%)比较差异无统计学意义.2组患者发生不良反应均在1月内恢复.实验组发生白细胞减少例数为10例,发生率为32.25%.对照组发生白细胞减少例数为18例,发生率为58.06%,差异具有统计学意义(P<0.05).结论 多西他赛联合卡铂方案与表柔比星联合环磷酰胺序贯多西他赛方案辅助治疗三阴性乳腺癌Ⅲ期患者均耐受,TP方案发生白细胞减少和脱发概率较低..%Objective To compare the clinical efficacy and safety of docetaxel combined with carboplatin (TP) and epirubicin combined with cyclophosphamide sequential docetaxel (EC-T) adjuvant in the treatment of three negative breast cancer in phase III . Methods 62 cases of three negative breast cancer patients in phase III from May 2012 to October 2016 were selected and randomly divided into the control group and the experimental group, with 31 patients in each group. The control group was treated with epirubicin combined with cyclophosphamide and sequential docetaxel, and the experimental group was treated with docetaxel and carboplatin. The clinical indicators were compared and analyzed. Results There was no significant difference in the recent remission rate (77.42%) between the experimental group and the control group (74.19%). Two groups of patients with adverse reactions were restored within one month. There were 10 cases of WBC decrease in the experimental group, with the incidence rate of 32.25%. There were 18 cases of WBC decrease in the control group, the incidence rate was 58.06%, the difference was statistically significant (P<0.05). Conclusion Docetaxel combined with carboplatin and epirubicin adjuvant combined with cyclophosphamide than star sequential docetaxel in the treatment of three patients with negative breast cancer stage III were tolerated, TP occurred leukopenia and alopecia with low probability.
展开▼
